BOSTON--(BUSINESS WIRE)--Silicon Therapeutics, an integrated physics-based drug discovery company creating novel small molecule therapeutics for diseases with challenging protein targets, announced today the appointment of Dr. Christopher Winter as Chief of R&D. Dr. Winter joins Silicon Therapeutics from Sanofi, where he led the company’s US Oncology Research as Site Lead and Research Cluster Head on Overcoming Immunosuppression.
“Silicon Therapeutics has assembled a world-class team applying an industry-leading platform to address fundamental challenges for designing next generation, breakthrough therapeutics,” said Dr. Winter. “I’m excited to join Silicon Therapeutics’ mission that joins integrated excellence in physics-based simulations, chemistry and disease biology focused on making drugs that matter for patients.”
“Chris brings to Silicon Therapeutics an outstanding track record of success in drug discovery and in building highly productive, multi-disciplinary research groups,” said Lanny Sun, CEO of Silicon Therapeutics. “We are pleased and honored that he will lead the build out and execution of our strategy to deploy our proprietary physics-based platform (INSITE) for the design of drugs against biologically promising targets that have been challenging to drug. His appointment represents the next phase in Silicon Therapeutics’ growth as it moves to enhance and expand drug discovery and R&D operations.”
Dr. Winter has held research leadership positions in pharmaceutical companies and emerging biotechnology firms over the past 15 years. During that time, he has delivered nine targeted cancer therapies into clinical testing. He joined Sanofi in 2013 as Sanofi Oncology’s Head of Discovery Biology and became site lead in 2015. He joined Sanofi from Blueprint Medicines, where he served as Head of Biology. The first biologist recruited by Blueprint, Dr. Winter built an outstanding interdisciplinary team and led the company’s first drug discovery project. The product of that effort, a first-in-class small molecule drug targeting FGFR4 for the treatment of liver cancer, is now advancing in clinical trials. Prior to Blueprint, Dr. Winter held senior research positions at Merck Research Laboratories and Exelixis, Inc. He received a B.S. degree in Biological Sciences from Binghamton University and a PhD in Biochemistry & Molecular Biophysics from Columbia University. He was a post-doctoral fellow at Stanford University in the Department of Biological Sciences.
SILICON THERAPEUTICS
Silicon Therapeutics, the first fully integrated physics-based drug discovery company, is focused on developing novel medicines for diseases with targets that are currently considered to be challenging for traditional approaches. Our INSITE platform closely represents the real dynamic nature of targets using accurate all-atom simulations, enabling us to discover, design, and optimize compounds for targets that were previously considered biologically validated, but difficult to drug. Our science, our team, and our mission are focused on applying advanced physics-based computational technologies to build and progress a pipeline of innovative medicines for patients. Silicon Therapeutics is headquartered in Boston, MA, USA with offices in Shanghai, China. Learn more at http://www.silicontx.com
